...A. We had double-digit growth in pharma for the third quarter in a row that represents roughly 30% of our revenue for those who are keeping score we saw continued strength in our -- or I should say we saw some rebound and strength in our key core pillars, growth pillars, that being our ProteinSimple franchise, third or fourth straight quarter of double-digit consumable growth, and we saw momentum pick up on the instruments in the back half of the quarter and into October, very encouraging to see. B. And as a reminder in our Q4 we had low single-digit declines in that business for us, which we were actually pleased with considering the overall market, but we saw that flatten out in our Q1 and more importantly we peel the onion back one level. C. Goals actually increased those single-digits and our instrument (inaudible) actually improved double-digit, so we see the Spatials turning a corner and returning to growth as well, which is encouraging. D. We saw the continued growth in China, now...
